Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., May 23, 2012 – Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 1-5, 2012. These data include oral presentations on clinical investigations of MLN9708, the first oral proteasome inhibitor being studied in patients with multiple myeloma. Also featured are poster discussions on clinical investigations of TAK-700, a selective 17,20 lyase inhibitor, dosed without steroids in patients with non-metastatic prostate cancer and trials of MLN8237, a selective Aurora A kinase inhibitor, in ovarian and breast cancer patients.

“Data being presented at this year’s ASCO meeting demonstrate the advancement of the Takeda oncology pipeline across a variety of solid tumors and hematologic malignancies,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium. “We are particularly pleased that this year’s presentations build on our expertise and leadership in protein homeostasis, as well as Takeda’s heritage in prostate cancer, while demonstrating our commitment to innovation and novel targets.”

MLN9708 Data

Key presentations will include:

• • Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): a phase 1/2 study
• • o Presenter: Paul Richardson, M.D., Dana-Farber Cancer Institute, Boston, MA
  • o Abstract #8033: Poster discussion session: Saturday, June 2, 12:00 p.m.

• • Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): a phase 1 study
• • o Presenter: Shaji Kumar, M.D.
  • o Abstract #8034: Poster discussion session: Saturday, June 2, 12:00 p.m.

• • Phase 1 study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM)
• • o Presenter: Sagar Lonial, M.D., Emory University, Atlanta, Georgia.
  • o Abstract #8017: Oral presentation session: Sunday, June 3, 8:00 am CT

TAK-700 data

Key presentations will include:

• • Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase 2 study
• • o Presenter: Daniel George, M.D., Duke University Medical Center, Durham, NC
  • o Abstract #4549: Poster discussion session: Monday, June 4, 11:30 a.m. CT

MLN8237 data

Key presentations will include:

• • Phase 1/2 study of weekly paclitaxel (P) with or without alisertib (A), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal (OC), or breast cancer: Phase 1 results
• • o Presenter: Gerald Falchook, M.D., M.D. Anderson Cancer Center, Houston, TX
  • o Abstract #5021: Poster discussion session: Friday, June 1, 4:30 p.m. CT

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/InTheNews.aspx.